10x Genomics FY2026 EPS Forecast Boosted by Leerink Partnrs

10x Genomics (NASDAQ:TXG) – Equities research analysts at Leerink Partnrs lifted their FY2026 earnings per share estimates for 10x Genomics in a research note issued to investors on Wednesday, November 19th. Leerink Partnrs analyst P. Souda now forecasts that the company will post earnings of ($0.95) per share for the year, up from their previous estimate of ($0.96). The consensus estimate for 10x Genomics’ current full-year earnings is ($1.43) per share.

A number of other brokerages have also recently issued reports on TXG. JPMorgan Chase & Co. lifted their price target on shares of 10x Genomics from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Zacks Research cut 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of 10x Genomics in a research report on Monday, November 17th. Deutsche Bank Aktiengesellschaft set a $14.00 target price on shares of 10x Genomics and gave the stock a “hold” rating in a research note on Friday, August 8th. Finally, Morgan Stanley decreased their price target on 10x Genomics from $18.00 to $17.00 and set an “overweight” rating for the company in a research note on Tuesday, August 12th. Six equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $14.88.

10x Genomics Trading Up 11.4%

Shares of 10x Genomics stock opened at $18.34 on Monday. 10x Genomics has a 12 month low of $6.78 and a 12 month high of $18.62. The firm has a market capitalization of $2.32 billion, a P/E ratio of -29.58 and a beta of 2.13. The business has a fifty day simple moving average of $13.41 and a two-hundred day simple moving average of $12.36.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.05. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.50%. The business had revenue of $149.00 million for the quarter, compared to analysts’ expectations of $142.50 million. During the same quarter in the previous year, the business posted ($0.30) earnings per share. The firm’s revenue for the quarter was down 1.7% compared to the same quarter last year. 10x Genomics has set its Q4 2025 guidance at EPS.

Institutional Trading of 10x Genomics

Hedge funds have recently bought and sold shares of the stock. ARK Investment Management LLC grew its stake in shares of 10x Genomics by 8.1% during the 2nd quarter. ARK Investment Management LLC now owns 13,892,103 shares of the company’s stock valued at $160,871,000 after acquiring an additional 1,046,390 shares during the period. Vanguard Group Inc. increased its stake in shares of 10x Genomics by 6.7% in the third quarter. Vanguard Group Inc. now owns 13,274,332 shares of the company’s stock worth $155,177,000 after purchasing an additional 834,272 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of 10x Genomics by 235.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company’s stock valued at $62,016,000 after purchasing an additional 4,987,195 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of 10x Genomics by 12.2% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,017,963 shares of the company’s stock valued at $69,688,000 after buying an additional 654,597 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. increased its stake in 10x Genomics by 12.1% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 6,009,653 shares of the company’s stock worth $69,532,000 after buying an additional 646,997 shares in the last quarter. Institutional investors own 84.68% of the company’s stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.